CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.
Panousis C, Dhagat U, Edwards KM, Rayzman V, Hardy MP, Braley H, Gauvreau GM, Hercus TR, Smith S, Sehmi R, McMillan L, Dottore M, McClure BJ, Fabri LJ, Vairo G, Lopez AF, Parker MW, Nash AD, Wilson NJ, Wilson MJ, Owczarek CM.
Panousis C, et al. Among authors: fabri lj.
MAbs. 2016;8(3):436-53. doi: 10.1080/19420862.2015.1119352. Epub 2015 Dec 14.
MAbs. 2016.
PMID: 26651396
Free PMC article.